Description
RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION. This product is sold exclusively for in vitro research and laboratory use by qualified professionals. It is not a drug, food, or cosmetic, and must not be administered to humans or animals. By purchasing, you agree to the site’s terms of use.
What is Retatrutide?
Retatrutide (LY3437943) is an investigational 39–amino acid synthetic peptide engineered as a triple agonist of the GLP-1, GIP, and glucagon receptors. It is among the newest and most extensively dose-ranged incretin compounds in development, with published Phase 2 clinical trials (TRIUMPH program) reporting body-weight reductions exceeding those observed with earlier dual-agonist peptides.
Mechanism of Action
- GLP-1 receptor agonism: glucose-dependent insulin secretion, suppressed glucagon, slowed gastric emptying, enhanced satiety
- GIP receptor agonism: synergistic incretin effect on insulin secretion
- Glucagon receptor agonism: hypothesized to increase energy expenditure via hepatic and adipose pathways
Compound Properties
- Molecular formula: C221H343N51O65
- Molecular weight: ~4,731 g/mol
- CAS number: 2381089-83-2
- Form: Lyophilized powder
- Source reference: PubChem CID 156588322
Research-Reference Dosing
Dosing from published peer-reviewed Phase 2 trials. Provided for research reference only; no regulatory approval exists.
- Phase 2 obesity trial: 1 mg, 4 mg, 8 mg, or 12 mg subcutaneous once weekly over 48 weeks after titration (Jastreboff et al., NEJM 2023)
- Phase 2 T2D trial: 0.5 mg – 12 mg subcutaneous weekly (Rosenstock et al., Lancet 2023)
- Typical titration: 2 mg starting dose with monthly increases as tolerated
Research Findings (Published Human Data)
- Phase 2 obesity (48 wks): mean body-weight reductions of ~17.5% (8 mg) and ~24.2% (12 mg)
- Phase 2 T2D (36 wks): HbA1c reductions up to ~2.0% with 12 mg dose
- Improvements in blood pressure, waist circumference, and lipid profile
- Phase 3 outcomes trials (TRIUMPH-1, -2, -3, -4) ongoing as of publication of most recent reports
Known Side Effects Reported in Trials
- Most common: nausea, diarrhea, vomiting, constipation, decreased appetite (dose-dependent)
- Less common: injection-site reactions, fatigue, increased heart rate
- Serious/rare reported in Phase 2: transient elevations in liver enzymes, gallbladder events, pancreatitis
- Note: long-term cardiovascular and thyroid safety data not yet available given investigational status
Storage & Handling
Store lyophilized vial at 2–8°C, protected from light. After reconstitution, refrigerate at 2–8°C. Do not freeze reconstituted solution.
Certificate of Analysis
A product-specific Certificate of Analysis (CoA) is available upon request for every lot.
